Rapamycin inhibits mTORC1, but not completely

Carson C Thoreen1, David M Sabatini

  • 1Whitehead Institute for Biomedical Research, Cambridge, MA, USA.

Autophagy
|April 28, 2009
PubMed

Insights

Rapamycin partially inhibits the mTORC1 complex. A new inhibitor, Torin1, reveals that key mTORC1 functions in translation and autophagy are resistant to rapamycin, highlighting its limitations.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cell Signaling

Background:

  • The mechanistic target of rapamycin complex 1 (mTORC1) is a central regulator of cell growth, metabolism, and survival.
  • Rapamycin is a widely used drug that inhibits mTORC1, but its precise mechanisms and limitations are still being investigated.

Purpose of the Study:

  • To investigate the full spectrum of mTORC1 functions regulated by nutrient-sensitive signaling.
  • To determine if mTORC1 functions are completely inhibited by rapamycin or if alternative pathways exist.

Main Methods:

  • Utilized a novel ATP-competitive inhibitor, Torin1, to probe mTORC1 activity.
  • Assessed the impact of Torin1 and rapamycin on cap-dependent translation and autophagy.

Main Results:

  • Identified specific mTORC1 functions, including regulation of cap-dependent translation and autophagy, that are resistant to rapamycin inhibition.
  • Demonstrated that Torin1 effectively inhibits these rapamycin-resistant mTORC1 activities.

Conclusions:

  • Rapamycin is not a complete inhibitor of all mTORC1 functions.
  • Novel inhibitors like Torin1 are crucial for fully understanding mTORC1 signaling pathways and their roles in cellular processes.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...